Global Growth USA Immuno-Oncology 2017-18
| Reference number | |
| Coordinator | IMMUNOVIA AB (PUBL) - IMMUNOVIA AB |
| Funding from Vinnova | SEK 58 892 |
| Project duration | November 2017 - April 2018 |
| Status | Completed |
| Venture | 2017-01599-en |
Important results from the project
The IO mission to US is expected to provide Immunovia with several new pharma partnership collaborations and hence the development of new innovative predictive (CDx) test solutions/products within IO. During the mission - we will initiate (and later follow-up) on partnering discussions with global pharma executives and identify suitable R&D partners and Clinical Development Centers for novel collaborations.
Expected long term effects
The project (i.e. the mission to US east coast) allowed Immunovia to meet several different companies and different investigators of relevance to Immunovia´s business development. On the company (pharma) side - 5 of the face-to-face meetings held during the US stay have led to follow-up activities/interactions between Immunovia and pharma. On the investigator ( NIH/NCI/Dana Farber etc.) side we experienced several relevant discussions with researchers/tech trans manegers/consultants with regard to the Immunovia technology platform (IMMrayTM).
Approach and implementation
Immunovia and two pharma companies/investigators are now discussing concrete project activities, where Immunovia will use it´s IMMrayTM platform to provide services to pharma in regard to patient sample differentiation.